Gate2Brain
Summary active Updated Jun 3, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Founders
About
Gate2Brain is a University of Barcelona spin-off founded in 2020 from IRB Barcelona, the University of Barcelona, and Hospital Sant Joan de Déu Barcelona, advancing a proprietary peptide-shuttle platform for transporting therapies across the blood-brain barrier to address paediatric and adult brain tumours and other central nervous system diseases 123. The company’s lead candidate, G2B-002, targets diffuse intrinsic pontine glioma (DIPG) and pediatric glioblastoma and has received Orphan Drug Designation from both the U.S. FDA and the European Medicines Agency 12.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-06-16 | Strategic Investment | €7M | Shilpa Biocare | – 123 |
Shilpa Biocare Pvt Ltd (a wholly owned subsidiary of Shilpa Medicare Limited) acquired a 30.4% equity stake. The €7M comprised €0.5M cash, €5.5M in equity for services, and €1M towards project development 23.
What Investors Say
No independently sourced investor quotes available at this time.
What Founders Say
CEO Meritxell Teixidó said: “This alliance will accelerate the development of G2B-002 and reinforce the validation of Gate2Brain’s proprietary technology platform for transporting therapies across the blood–brain barrier” 2.
Teixidó also said: “Gate2Brain acknowledges the continued support of its institutional partners, external advisors, investors and business angels, whose confidence and commitment have played a key role in advancing the company’s mission and technology platform” 2.
Sources
-
EU-Startups, “Barcelona-based Gate2Brain secures €7 million to advance brain tumour candidate,” June 16, 2026. Accessed June 2026. https://www.eu-startups.com/2026/06/barcelona-based-gate2brain-secures-e7-million-to-advance-brain-tumour-candidate/↩↩↩
-
Parc Científic de Barcelona, “Gate2Brain signs a strategic alliance with Shilpa Biocare with a €7 million investment,” June 16, 2026. Accessed June 2026. https://www.pcb.ub.edu/en/gate2brain-signs-a-strategic-alliance-with-shilpa-biocare-with-a-e7-million-investment/↩↩↩↩↩↩
-
Fundació Bosch i Gimpera, “Gate2Brain secures a €7 million investment to advance its lead therapeutic candidate for the treatment of rare and aggressive brain tumours,” June 16, 2026. Accessed June 2026. https://www.fbg.ub.edu/en/news/gate2brain-secures-a-e7-million-investment-to-advance-its-lead-therapeutic-candidate-for-the-treatment-of-rare-and-aggressive-brain-tumours/↩↩↩